BCRX vs KRYS
BCRX: BioCryst Pharmaceuticals is a biotech company focused on commercializing and developing innovative therapies for hereditary angioedema and other rare diseases using structure-guided drug design. KRYS: Krystal Biotech is a genetic medicine company leveraging its proprietary HSV-1 vector platform to treat rare diseases, headlined by its FDA-approved topical gene therapy for dystrophic epidermolysis bullosa.
Side-by-side fundamentals
| Metric | BCRX | KRYS | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $9.58 | $351.82 | |
| Market cap as of 2026-07-30 | $2.4B | $10.7B | |
| P/E as of 2026-07-30 | 9.22 | 47.46 | BCRX lower |
| PEG as of 2026-07-30 | -0.01 | 0.72 | BCRX lower |
| Net margin as of 2026-07-30 | -51.7% | +53.9% | KRYS higher |
| Gross margin as of 2026-07-30 | +97.8% | +94.2% | BCRX higher |
| Operating margin as of 2026-07-30 | -45.1% | +42.8% | KRYS higher |
| ROE as of 2026-07-30 | -328.8% | +19.3% | KRYS higher |
| ROA as of 2026-07-30 | -97.3% | +17.6% | KRYS higher |
| Debt / equity as of 2026-07-30 | 2.26 | 0.00 | KRYS lower |
| Revenue growth (YoY) as of 2026-07-30 | +75.9% | +25.1% | BCRX higher |
| Revenue CAGR (3y) SEC XBRL | +22.8% | n/a | |
| Beta as of 2026-07-30 | 0.57 | 0.54 | |
| 1-year return as of 2026-07-27 close | +12.0% | +138.3% | KRYS higher |
Fundamentals: market data, as of 2026-07-30. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.